Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

Clark, Richard E ORCID: 0000-0002-1261-3299, Apperley, Jane F, Copland, Mhairi and Cicconi, Silvia (2021) Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. BLOOD ADVANCES, 5 (4). pp. 1102-1109.

Text
advancesadv2020003570.pdf - Published Version
Download (890kB) | Preview

Official URL: http://dx.doi.org/10.1182/bloodadvances.2020003570

Abstract

At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia (Ph) translocation confer a higher risk of subsequent disease progression. In the United Kingdom SPIRIT2 trial comparing imatinib 400 mg daily with dasatinib 100 mg daily, diagnostic karyotypes were available in 763 of the 814 patients recruited. Of these, 27 had ACAs in either/both the original 4 major route group (trisomy 8 or 19, iso17q or a second Ph) or the 5 additional lesions recently described (trisomy 21, 3q26.2, monosomy 7/7q-, 11q23, and complex karyotypes), and their progression rate was significantly higher (22.2%) than in patients without one of these ACAs (2.2%; P < .001). Patients with ACAs had worse progression-free survival (PFS; hazard ratio [HR], 5.21; 95% confidence interval [CI], 2.59-10.50; P < .001) and freedom from progression (FFP; HR, 12.66; 95% CI, 4.95-32.37; P < .001) compared with patients without ACAs. No association was seen between the Sokal or European Treatment and Outcome Study long-term survival (ELTS) scores and the presence of ACAs. Univariate analysis showed that higher Sokal and ELTS scores and the presence of ACAs were associated with poorer PFS, though only ACAs and high-risk ELTS scores were associated with poorer FFP. Multivariable models identified both the Sokal/ELTS score and ACAs as significant independent factors for PFS but only ELTS score and ACAs as significant independent factors for FFP. The data support the view that certain ACAs are predictive of disease progression independently of Sokal or ELTS scores.

Item Type:	Article
Uncontrolled Keywords:	Humans, Leukemia, Myeloid, Chronic-Phase, Chromosome Aberrations, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib Mesylate, United Kingdom
Depositing User:	Symplectic Admin
Date Deposited:	01 Mar 2021 14:16
Last Modified:	18 Jan 2023 22:58
DOI:	10.1182/bloodadvances.2020003570
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3116312